


Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study

Su Yin Lim ¹, Laura Ferro Lopez ¹, Elizabeth Barquin ¹, Daniel Lindsay ¹, Khin Thway ^{1,2}, Myles J Smith ^{1,2}, Charlotte Benson ¹, Robin L Jones ^{1,2} and Andrea Napolitano ¹

1. The Royal Marsden NHS Foundation Trust, London SW3 6JJ, United Kingdom
2. The Institute of Cancer Research, London SW7 3RP, United Kingdom

- **Supplementary Figure S1.** PFS ripretinib BD
- **Supplementary Table S1.** Differences in baseline patient characteristics stratified by ripretinib OD TBP
- **Supplementary Table S2.** Univariate and multivariate Cox regression model for OS

Supplementary Figure S1. PFS ripretinib BD



Supplementary Table S1. Differences in baseline patient characteristics stratified by ripretinib OD TBP

Ripretinib OD TBP	No	Yes	P value
Number of patients	31	14	
Sex: Male	19 (61.3%)	7 (50%)	0.701
Age (mean, standard deviation)	63 (10)	64 (15)	0.672
Primary mutational status			0.569
- <i>KIT</i> exon 11	24 (77.4%)	9 (64.3%)	
- <i>KIT</i> exon 9	2 (6.5%)	1 (7.1%)	
- <i>PDGFRA</i>	1 (3.2%)	2 (14.3%)	
- N/A	4 (12.9%)	2 (14.3%)	
Primary tumour site			0.026
- Stomach	9 (29.0%)	4 (28.6%)	
- Small bowel	19 (63.3%)	4 (28.6%)	
- Other	3 (9.7%)	6 (42.9%)	
Stage: metastatic	31 (100.0%)	13 (92.9%)	0.680
Number of metastatic sites			0.342
- 1 site	9 (29.0%)	7 (50%)	
- 2 sites	13 (41.9%)	5 (35.7%)	
- 3 or more sites	9 (29.0%)	2 (14.3%)	
ECOG			0.484
- 0	1 (3.2%)	0 (0.0%)	
- 1	28 (90.3%)	14 (100.0%)	
- 2	2 (6.5%)	0 (0.0%)	
Number of previous lines: 3 or more	20 (64.5%)	6 (42.9%)	0.300
Previous lines			
- Sunitinib	30 (96.8%)	13 (92.9%)	1.000
- Regorafenib	19 (61.3%)	5 (35.7%)	0.204
- Avapritinib	9 (29.0%)	4 (28.6%)	1.000

Supplementary Table S2. Univariate and multivariate Cox regression model for OS.

Variable	Univariate HR (95% CI)	P value	Multivariate HR (95% CI)	P value
Sex (male vs female)	2.45 (1.02–5.91)	0.045 *	1.70 (0.66–4.38)	0.272
Age	1.00 (0.97–1.03)	0.951	NI	
Primary mutation (others vs <i>KIT</i> exon 11)	3.39 (1.30–8.82)	0.012 *	4.19 (1.49–11.82) *	0.007 *
Primary tumour site			NI	
- Small bowel vs gastric	1.08 (0.45–2.60)	0.872		
- Others vs gastric	0.70 (0.21–2.34)	0.566		
Number of metastatic sites				
- 2 vs 0/1	1.44 (0.55–3.78)	0.462	1.01 (0.35–2.97)	0.981
- 3 or more vs 0/1	2.16 (0.78–5.96)	0.139	2.37 (0.74–7.56)	0.145
Number of previous lines (3 or more vs 2)	0.98 (0.44–2.19)	0.961	NI	
Previous regorafenib	1.04 (0.51–2.11)	0.919	NI	
Previous avapritinib	1.25 (0.57–2.72)	0.578	NI	

NI: not included